Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)

Background: Lamivudine is an established treatment options for chronic hepatitis B (CHB), however development of viral resistance followed by virological breakthrough made it a less favourable as a first line treatment option. While the alternatives such as entecavir and tenofovir are favoured for...

Full description

Saved in:

Bibliographic Details
Main Author:	Ismail, Mohd Sharizan
Format:	Thesis
Language:	English
Published:	2018
Subjects:	RA643-645 Disease (Communicable and noninfectious) and public health
Online Access:	http://eprints.usm.my/46573/1/Dr.%20Mohd%20Sharizan%20Ismail-24%20pages.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.46573
record_format	uketd_dc
spelling	my-usm-ep.465732020-06-14T04:06:46Z Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM) 2018 Ismail, Mohd Sharizan RA643-645 Disease (Communicable and noninfectious) and public health Background: Lamivudine is an established treatment options for chronic hepatitis B (CHB), however development of viral resistance followed by virological breakthrough made it a less favourable as a first line treatment option. While the alternatives such as entecavir and tenofovir are favoured for first line options due to its higher genetic barrier to resistance, constraints such as financial issue may not make these drugs readily available in some practice. Objectives: The aim of the study is to established period prevalence of lamivudine resistance among patient with CHB who received Lamivudine from January 2010 to Dec 2016, and to explore if there are any factors that associate with development of resistance. The study also aims to look at the response rate for those treated with lamivudine during the same period. Methods This is a retrospective record review done by reviewing record of 41 patients who was or on lamivudine during the period of 2010 to 2016. Subjects are CHB patient who are treated with lamivudine as a first line monotherapy. All relevant data are gathered from the review of case note and recorded in statistical software for analysis. Results Total number of patients included in this study is 41. During the 6 years periods, 9 patients with lamivudine resistance were detected and this yields an overall period prevalence of 21.9%. The cumulative incidence of developing resistance during first year, second year and third year while on lamivudine is 4.9%, 12.2% and 21.9% respectively. Factors such as age, gender, race, pre-treatment viral load, serum ALT, and duration of treatment are shown not associated with development of resistance. In terms of response to treatment, this study shows an overall response rate of 89.5%. Conclusion The prevalence and incidence of lamivudine resistance in this study is lower in comparison with the prevalence and cumulative incidence cited in many literatures. However, further study is warranted to include more patients from other centres in order to improve power of this study, before any recommendation can be proposed. 2018 Thesis http://eprints.usm.my/46573/ http://eprints.usm.my/46573/1/Dr.%20Mohd%20Sharizan%20Ismail-24%20pages.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	RA643-645 Disease (Communicable and noninfectious) and public health
spellingShingle	RA643-645 Disease (Communicable and noninfectious) and public health Ismail, Mohd Sharizan Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
description	Background: Lamivudine is an established treatment options for chronic hepatitis B (CHB), however development of viral resistance followed by virological breakthrough made it a less favourable as a first line treatment option. While the alternatives such as entecavir and tenofovir are favoured for first line options due to its higher genetic barrier to resistance, constraints such as financial issue may not make these drugs readily available in some practice. Objectives: The aim of the study is to established period prevalence of lamivudine resistance among patient with CHB who received Lamivudine from January 2010 to Dec 2016, and to explore if there are any factors that associate with development of resistance. The study also aims to look at the response rate for those treated with lamivudine during the same period. Methods This is a retrospective record review done by reviewing record of 41 patients who was or on lamivudine during the period of 2010 to 2016. Subjects are CHB patient who are treated with lamivudine as a first line monotherapy. All relevant data are gathered from the review of case note and recorded in statistical software for analysis. Results Total number of patients included in this study is 41. During the 6 years periods, 9 patients with lamivudine resistance were detected and this yields an overall period prevalence of 21.9%. The cumulative incidence of developing resistance during first year, second year and third year while on lamivudine is 4.9%, 12.2% and 21.9% respectively. Factors such as age, gender, race, pre-treatment viral load, serum ALT, and duration of treatment are shown not associated with development of resistance. In terms of response to treatment, this study shows an overall response rate of 89.5%. Conclusion The prevalence and incidence of lamivudine resistance in this study is lower in comparison with the prevalence and cumulative incidence cited in many literatures. However, further study is warranted to include more patients from other centres in order to improve power of this study, before any recommendation can be proposed.
format	Thesis
qualification_level	Master's degree
author	Ismail, Mohd Sharizan
author_facet	Ismail, Mohd Sharizan
author_sort	Ismail, Mohd Sharizan
title	Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
title_short	Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
title_full	Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
title_fullStr	Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
title_full_unstemmed	Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)
title_sort	period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis b patient in hospital universiti sains malaysia (husm)
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2018
url	http://eprints.usm.my/46573/1/Dr.%20Mohd%20Sharizan%20Ismail-24%20pages.pdf
_version_	1747821688617172992

Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)

Similar Items